Opendata, web and dolomites

PoC-Cycle

Innovative Molecular Diagnostics point-of-care device for MRSA

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PoC-Cycle project word cloud

Explore the words cloud of the PoC-Cycle project. It provides you a very rough idea of what is the project "PoC-Cycle" about.

platform    deaths    infections    appropriate    rapid    pathogens    few    patients    mrsa    administration    diagnose    device    health    17    pilot    spread    sensitive    reduce    tuberculosis    workflow    robustness    microarrays    feasibility    point    cycle    ing    friz    hospitals    missing    microfluidic    turnover    efficient    optimized    hpv    screening    multiplex    signatures    diagnostics    innovative    multiplexing    forecast    sensitivity    semiconductor    limited    platforms    collection    experts    discuss    interviewing    multicentric    detection    accuracy    almost    acid    usability    business    million    prepares    format    combination    safe    mostly    care    variations    handling    approx    version    reg    900    poc    tests    negative    area    checked    2015    fast    broad    routine    introducing    operate    yearly    disposable    diagnostic    diagnosis    revised    technically    market    sequence    freedom    nucleic    acceptance    provides    significantly    complexity    pcr    pathogen    cartridge    validation    biomarkers   

Project "PoC-Cycle" data sheet

The following table provides information about the project.

Coordinator
FRIZ BIOCHEM GMBH 

Organization address
address: FLORIANSBOGEN 2-4
city: NEURIED
postcode: 82061
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.frizbiochem.de
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2014
 Duration (year-month-day) from 2014-09-01   to  2014-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FRIZ BIOCHEM GMBH DE (NEURIED) coordinator 50˙000.00

Map

 Project objective

FRIZ has developed PoC-Cycle® platform- an innovative diagnostics device introducing efficient multiplex nucleic acid testing to the point-of-care. It provides a combination of accuracy and sensitivity, multiplexing, and optimized workflow from sample collection to diagnosis. Current diagnostics platforms are technically limited: On one side only few sequence signatures can be checked, on the other side, the analysis of these signatures are mostly considered in one sequence area only due to the high complexity in developing Multiplex-PCR, as well as missing process-robustness for routine administration. FRIZ implemented a multiplex analysis in disposable microfluidic cartridge format with integrated semiconductor based on microarrays for the rapid and sensitive detection of a broad range and number of biomarkers. Key market is the screening of MRSA, a pathogen with wide spread and growing negative impact to European patients and health care systems. Experts forecast the number of deaths will increase from 6,000 to approx. 17,000 in 2015. Main users of the device are hospitals as they require simple and safe handling as well as fast and reliable results. European market potential can be estimated with 900,000 tests per year resulting in a yearly turnover of almost two million €. The new diagnostic device will significantly reduce the number of infections. Moreover, it provides future business opportunities due to its general approach for diagnose further pathogens e.g. HPV or tuberculosis. Within the project, FRIZ aims to identify end-users for validation, discuss the handling and identify possible variations to enhance the usability and acceptance of the new system in phase 2. To find an appropriate partner for validation is also part of this feasibility study. In addition, FRIZ prepares a revised version of a “freedom-to-operate” analysis. A multicentric validation study is planned as well as interviewing end-users and built up a pilot production in phase 2.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "POC-CYCLE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "POC-CYCLE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More